Search results
Results from the WOW.Com Content Network
Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. [1] Most people have no symptoms while others develop calcium deposits in the soft tissue. [1] The disorder is often accompanied by low calcium blood levels, which can result in muscle spasms. [1]
Hyperphosphatemia causes acute kidney injury in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma. [2] Hypocalcemia. Because of the hyperphosphatemia, calcium is precipitated to form calcium phosphate, leading to hypocalcemia. [2] Symptoms of hypocalcemia include (but are not limited to): [9] tetany
As well as providing samples and personal data from questionnaires, surveys and feedback, participants agree to allow the project to access their present and future records held by the NHS. [16] The project has the support of the government, the life sciences industry, the NHS, and charities such as Alzheimer's Society, British Heart Foundation ...
Sevelamer is a phosphate binding medication used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals.
As a research funder and research partner of the NHS, public health and social care, the NIHR complements the work of the Medical Research Council. [5] NIHR focuses on translational research (translating discoveries from the laboratory to the clinic), clinical research and applied health and social care research.
There have been limited trials comparing phosphate binders to placebo in the treatment of hyperphosphatemia in people with chronic kidney disease. When compared with people receiving calcium-based binders, people taking sevelamer have a reduced all-cause mortality. [4]
The NHS in Wales was also running a national programme for service improvement and development via the use of information technology – this project was called Informing Healthcare. A challenge facing both NHS CFH and Informing Healthcare was that the use of national systems previously developed by the NHS Information Authority were shared by ...
The NHS Institute for Innovation and Improvement (NHS Institute) was a special health authority of the National Health Service in England.It supported "the NHS to transform healthcare for patients and the public by rapidly developing and spreading new ways of working, new technology and world-class leadership".